A phase 0/I clnical trial investigating the tolerability and pharmacokinetics of soluble FC-GAMMA IIB receptor SM101 as potential therapy in autoimmune diseases in healthy volunteers.

At a glance
Trial Overview
Trial Details
Interventions
Results
Authors
Trial Centres
- Investigators
- Centres
Trial History
References

Trial Profile

A phase 0/I clnical trial investigating the tolerability and pharmacokinetics of soluble FC-GAMMA IIB receptor SM101 as potential therapy in autoimmune diseases in healthy volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Jun 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Valziflocept (Primary)
Indications Systemic lupus erythematosus
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

17 Jun 2011 adnms added, start date added etc from 9126093
28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
28 May 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com